California’s state-backed generic drug initiative, CalRx, faces a slow start at retail pharmacies despite offering long-acting insulin glargine pens for a recommended price of $11 each. Governor Gavin Newsom introduced … Read More
Recent clinical findings published in Nature detail an investigative approach for acute traumatic spinal cord injury (SCI): the intramedullary injection of polymerized laminin. Conducted across public and private hospitals in … Read More
The California Supreme Court has ruled in favor of Gilead Sciences in a closely watched lawsuit involving more than 24,000 patients. The plaintiffs argued the pharmaceutical company acted negligently by … Read More
Sleep apnea therapeutic developer Apnimed secured $192 million in an initial public offering as markets opened in late July 2026. The funding arrives as the clinical-stage pharmaceutical company prepares for … Read More
In a phase 1 clinical trial published this week in Nature Medicine, the combination of englumafusp alfa and glofitamab demonstrated manageable safety and preliminary efficacy in patients with relapsed or … Read More
Researchers have developed COMPASS, a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes. In Plain English: The Clinical Takeaway Predictive Accuracy: COMPASS … Read More
AI company Anthropic announced plans to try to make drugs, leveraging its Claude Science application to address real scientific problems. The move marks a shift from software to pharmaceuticals, though … Read More
Researchers have successfully utilized a refined CRISPR-based technique, known as base editing, to modify human embryos in a laboratory setting. Published in the journal Nature, this study indicates that base … Read More
Researchers have successfully utilized Chimeric Antigen Receptor (CAR) T cell therapy to target smoldering multiple myeloma, an asymptomatic precursor to bone marrow cancer. Published in Nature Medicine this June, the … Read More
A first-in-human phase 1 trial published this week in Nature Medicine found an experimental vaccine combining inactivated rabies virus and Lassa fever antigens—with an adjuvant to boost immune response—to be … Read More
